Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients by Han, Alice et al.
Current Problems in Cancer: Case Reports 3 (2021) 100057 
Contents lists available at ScienceDirect 
Current Problems in Cancer: Case Reports 
journal homepage: www.elsevier.com/locate/cpccr 
Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of 
allogeneic peripheral blood stem cell transplant recipients 
Alice Han a , ∗ , Tulio E. Rodriguez b , Eric T. Beck c , Ryan F. Relich d , Dioma U. Udeoji e , 
Robert Petrak f , Vishnu V. Chundi g 
a Metro Infectious Disease Consultants, 901 McClintock Drive, Suite 201, Burr Ridge, Chicago, IL 60527, United States 
b Department of Medicine, Advocate Lutheran General Hospital, Advocate Aurora Health, Rosalind Franklin University of Medicine and Science, North Chicago, United 
States 
c Department of Microbiology, ACL Laboratories, Advocate Aurora Health, United States 
d Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, United States 
e Department of Internal Medicine, Advocate Lutheran General Hospital, United States 
f Department of Internal Medicine, Advocate Lutheran General Hospital, United States 
g Metro Infectious Disease Consultants, Chicago, Illinois, United States 
a r t i c l e i n f o 
Keywords: 
COVID-19 
Sars-CoV-2 
Persistent infection 
Positive culture 
PBSCT 
HSCT 
a b s t r a c t 
The coronavirus disease 19 (COVID-19) pandemic has infected tens of millions across the world, but there is 
a significant gap in our understanding about COVID-19 in the hematopoietic stem transplant (HSCT) recipient 
population. Prolonged viral shedding is frequently observed with severe acute respiratory syndrome coronavirus- 
2 (SARSCoV-2), but studies suggest viral loads decline 10 days after symptom onset. Current CDC guidance 
suggests that severely ill and immunocompromised hosts are no longer infectious after 20 days from symptom 
onset. Cycle threshold (Ct) values are inversely proportional to the viral load and are used to detect SARS-CoV-2 
RNA concentration. Specimens with reverse transcriptase PCR (RT-PCR) Ct values > 33–34 have been associated 
with inability to culture virus, and have been used as a surrogate for diminished infectivity. We report two cases 
of allogeneic peripheral blood stem cell transplant (PBSCT) recipients who had prolonged durations of infectivity 
with SARSCov-2, based on culture positivity and persistently low Ct values for greater than 50 days. 
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The coronavirus disease 19 (COVID-19) pandemic has infected hun-
reds of millions across the world, but there is a significant gap in our
nderstanding about COVID-19 in the hematopoietic stem transplant
HSCT) recipient population. Prolonged viral shedding is frequently ob-
erved with severe acute respiratory syndrome coronavirus-2 (SARS-
oV-2), but studies suggest viral loads decline 10 days after symptom
nset. Current CDC guidance suggests that severely ill and immunocom-
romised hosts are no longer infectious after 20 days from symptom on-
et. Cycle threshold (Ct) values are inversely proportional to the viral
oad and are used to detect SARS-CoV-2 RNA concentration. Specimens
ith reverse transcriptase PCR (RT-PCR) Ct values > 33–34 have been
ssociated with inability to culture virus, and have been used as a surro-
ate for diminished infectivity. We report two cases of allogeneic periph-
ral blood stem cell transplant (PBSCT) recipients who had prolonged
urations of infectivity with SARS-Cov-2, based on culture positivity and
ersistently low Ct values for greater than 50 days. ∗ Corresponding author. 
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Patient 1 is a 26-year-old male with relapsed refractory pre-B cell
cute lymphoblastic leukemia who underwent an allogeneic haploiden-
ical PBSCT on April 13, 2020. He was treated with the CALGB 10,403
egimen, followed by vincristine, daunorubicin, PEG asparaginase, and
ntrathecal methotrexate plus cytarabine. He received central nervous
ystem prophylaxis with intrathecal methotrexate and cytarabine. He
hen underwent an allogeneic haploidentical PBSCT with a condition-
ng regimen of busulfan, fludarabine, and cyclophosphamide. Graft ver-
us host disease (GVHD) prophylaxis consisted of post-transplant cy-
lophosphamide, tacrolimus and mycophenolate. Mycophenolate was
nitiated on day 5 post-transplantation and continued for 30 days. His-
eutrophils engrafted on day 15 post-PBSCT; however, he remained
ancytopenic and persistently lymphopenic. His-day 30 post-PBSCT
himerism showed 100% CD33 + and 33% CD3 + donor cells. 
On day 38 post-PBSCT, he developed a fever to 38.3 °C and a dry
ough. He reported abdominal pain and diarrhea the following week.
n day 52 post-PBSCT, a nasopharyngeal swab (NP) from the patient 14 January 2021 
ticle under the CC BY-NC-ND license 
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Fig. 1. 
Table 1 
Results of NP rapid SARS-Cov-2 PCR for patient 1. 
Illness day 15 Illness day 54 Illness day 59 Illness day 63 Illness day 86 
Treatment day of remdesivir Treatment Day 0 Treatment Day 0 Treatment Day 6 Treatment Day 10 
Rapid SARS Cov-2 PCR Positive Positive Positive Positive Positive 
Ct N2 value 19.9 23.2 27.8 22.5 41.5 
Ct values were all reported using Xpert Xpress SARS-CoV-2 Assay. Only N2 values are reported in this case report. 
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ested positive for SARS-CoV-2 (N2 Ct = 19) by RT-PCR, using the Xpert
press SARS-CoV-2 Assay. His-initial chest radiograph showed bilateral
nterstitial infiltrates ( Fig. 1 ). He was notably pancytopenic with a CMV
iral load of 2091,000 IU/mL. G-CSF was started for leukopenia. GVHD
rophylaxis with tacrolimus was discontinued on day 58 post-PBSCT.
e was treated with 24 days of ganciclovir and 5 days of remdesivir.
e received dexamethasone for 6 days for hypoxemia. ( The RECOVERY
ollaborative Group, 2020 ) On day 67 post-PBSCT, he developed graft
ailure (absolute neutrophil count < 0.5 K/ 𝜇l despite daily G-CSF). He
as discharged home with valganciclovir with a CMV viral load of 1330
U/mL. He remained persistently SARS-CoV-2 RT-PCR positive 20 and
3 days post initial test. After 28 days of isolation, he returned to the out-
atient infusion center for biweekly transfusions. His-day 72 post-PBSCT
himerism showed 96% CD33 + and 1% CD3 + donor cells, suggesting
rogression of the recipient’s lymphocyte reconstitution with an initial
oss of donor myeloid engraftment. 
Fifty-three days post-initial onset of COVID-19 symptoms, he re-
orted worsening cough and fever up to 39.8 °C. Repeat chest radio-
raph showed worsening infiltrates. Repeat RT-PCR testing 54 days post
ymptom onset using the same Xpert Xpress SARS-CoV-2 Assay was pos-
tive (N2 Ct = 23.2). In addition to a positive RT-PCR result, viral culture
as performed off the NP swab collected on day 54 at a biosafety level-3
ab, and it showed the presence of infectious SARS-CoV-2. 
He was restarted on remdesivir for 10 days. On day 5 of remde-
ivir, his fever, cough and radiographic findings improved, however,
epeat RT-PCRs with the Xpert Xpress SARS-CoV-2 Assay were positive
t day 59 (N2 Ct = 27) and day 63 of illness onset (N2 Ct = 22) ( table
 ). His-SARS-CoV-IgG antibody at day 56 post illness onset was nega-
ive. On day 86 post illness onset, his RT-PCR Ct value eventually in-
reased to 41.5, deeming him noninfectious. He remained pancytopenic
ith an absolute neutrophil count of 0 despite daily g-CSF. His-day2 3 post-PBSCT chimerism showed incalculable CD33 + and 0% CD3 +
onor cells. His-bone marrow biopsy on day 113 post-PBSCT showed a
ypocellular bone marrow with early regenerative activity and no mor-
hologic evidence of residual leukemic blasts. His-chimerism from the
one marrow showed 63% CD33 + and 0% CD3 + donor cells compatible
ith full recipient lymphocyte reconstitution and progressive loss of his
onor myeloid engraftment. 
Following loss of his graft, the patient underwent a stem cell boost on
ay 125 post PBSCT with minimal change in his pancytopenia. He ulti-
ately required a second allogeneic haploidentical PBSCT, preceded by
 regimen of fludarabine, cyclophosphamide and anti-thymocyte globu-
in. Neutrophils engrafted 12 days post PBSCT. His-post transplant bone
arrow chimerism on day 91 post second PBSCT revealed 98.7% CD33 +
nd 98.7% CD3 + donor cells, indicating near complete donor engraft-
ent. His-bone marrow biopsy showed a hypercellular bone marrow
ith marked erythroid predominance, reduced myeloid precursors and
eutrophils, and no evidence of leukemia. 
Our second patient is a 23 year old female with acute myeloid
eukemia (AML) who initially received induction chemotherapy with cy-
arabine and daunorubicin followed by re-induction with mitoxantrone,
toposide and cytarabine. She required salvage chemotherapy with flu-
arabine, cytarabine, idarubicin, and gemtuzumab ozogamicin due to
elapse. She underwent an allogeneic matched related PBSCT, follow-
ng a conditioning regimen of busulfan and cytoxan. Her neutrophils
ngrafted on day 12 post-PBSCT. Her day 100 post-PBSCT bone mar-
ow biopsy showed slightly hypercellular bone marrow (50% cellular)
ith normal dysplasia, mildly increased blasts (approximately 3% of
arrow cellularity) and hematogones (10%), compatible with regener-
tive changes. Because the day 100 post-PBSCT chimerism showed 97%
onor cells, 3% recipient cells and high risk of disease, she was started
n low dose azacitadine maintenance treatment. 
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Table 2 
Results of NP Rapid SARS-Cov-2 PCR for patient 2. 
Date Day 0 Day 7 Day 24 Day 49 Day 56 
Rapid SARS Cov-2 PCR Positive Positive Positive Positive Positive 
Ct N2 value 14.7 17.4 17.1 28.9 34.1 
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w  She developed persistent pancytopenia and repeat bone marrow
iopsy three months later showed relapsed AML with 55–60% blasts,
hich were positive for CD15, CD33, CD34, CD45, CD117. She failed
einduction with clofarabine and cytarabine. She was started on sal-
age chemotherapy with topotecan, vinorelbine, thiotepa, gemcitabine,
nd dexamethasone. Her hospital course was complicated by cardio-
enic shock with an ejection fraction of 15–20%, wide open tricuspid
egurgitation, and mild to moderate aortic valve regurgitation. She re-
uired mechanical ventilation in the intensive care unit (ICU) and was
oted to have bloody secretions. SARS-CoV-2 RT-PCR testing was neg-
tive at that time. She developed enterococcus bacteremia, related to
 line infection and received 14 days of linezolid. She was also started
n isavuconazole for a presumed pulmonary angioinvasive mold infec-
ion per her clinical symptoms and imaging. CT chest showed multiple
ulmonary nodules with surrounding linear lucencies consistent with
n angioinvasive fungal infection. She clinically improved, was subse-
uently extubated and transferred out of the ICU. 
While on the medical ward, she was exposed to a nurse who later
ested positive for SARS-CoV-2. The nurse was asymptomatic at the time
he took care of the patient but developed symptoms shortly thereafter.
s part of the exposure workup given the known presymptomatic and
symptomatic spread with SARS-CoV-2, ( Gandhi et al., 2020 ) ( Arons et
l., 2020 ) ( Tong et al., 2020 ) the patient was tested for SARS-CoV-2 by
T-PCR, using the Xpert Xpress SARS-CoV-2 assay and tested positive.
he was asymptomatic at the time of testing. Because of her severely im-
unocompromised state and high risk of complications, she was treated
ith 5 days of Remdesivir. She remained asymptomatic throughout the
ourse of treatment. On day 24 post diagnosis, repeat RT-PCR using the
ame Xpert Xpress SARS-CoV-2 methodology, revealed a Ct of 17.1. On
ay 41 post diagnosis, patient received convalescent plasma to aid her
mmune response and clearance of the virus. At 49 days post diagnosis,
er RT-PCR Ct value increased to 28.9. At day 56 post diagnosis, her
T-PCR CT value increased to 34.1, deeming her noninfectious ( Table
 ). 
iscussion 
SARS-CoV-2 has been recognized to cause prolonged viral shedding
n the nasopharynx, but previous studies have established that the vi-
al load rapidly decreases after day 10 of symptoms. ( Liu et al., Aug )
ultiple studies have indicated that transmission occurs early, predom-
nantly in the first week of symptoms. ( Cheng et al., 1 ) ( Wolfel et al.,
020 ) Understanding the transmission pattern in relation to levels of
iral shedding has guided infection control principles in managing the
ARS-CoV-2 pandemic. ( Atkinson and Petersen, 2020 ) ( Hei et al., 2020 )
urrent CDC guidance recommends using a symptom-based strategy for
iscontinuing transmission-based precautions. ( CDC 2020 ) For patients
ith mild to moderate illness who are not severely immunocompro-
ised, transmission-based precautions can be discontinued after 10 days
rom symptom onset if the patient has been afebrile for 24 h and if the
ymptoms have improved. A duration of 20 days has been proposed
or patients with critical illness or for patients who are severely im-
unocompromised. Previous studies have proposed that the presence of
eutralizing antibody is associated with the presence of non-infectious
ARS-CoV-2 and decreased infectivity of persistently positive patients.
 Van Kampen et al., 2020 ) 
Our first patient is unique in that he acquired SARS-CoV-2 < 40 days
ost allogeneic PBSCT with a naive immune system that was incapable3 f producing the T cell mediated or neutralizing antibody responses that
re fundamental for viral clearance. Repeated testing demonstrated per-
istently low RT-PCR Ct values (in the 20 s) up to 63 days post initial
ymptom onset with symptom recurrence and culture positivity at day
4 post symptom onset, indicating ongoing infectivity. Cycle thresholds
ave been used as an indicator of viral load ( Yu et al., 2020 ) ( Liu et
l., 19 ) and specimens with RT-PCR Ct values greater than 33–34 have
een associated with inability to culture virus. ( La Scola et al., 2020 )
n the Korean CDC epidemiological investigation for 447 “re-positive ”
ases, Ct values for 93 samples tested showed 89.5% of the tests had a Ct
alue > 30 and all the cases had neutralizing antibody production. None
f these cases contributed to secondary cases. ( KDCA 19 May 2020 ) In
ontrast, our first patient had no detectable SARS-CoV-2 IgG, and his NP
ARS-CoV-2 RT-PCRs had consistently low N2 Ct values in the 20 s. It is
mportant to note that the same platform was used to determine the N2
t value as Ct values across different assays can vary in their correlation
f detection of SARS-CoV-2 RNA. ( Moore et al., 2020 ) His-recrudescence
f symptoms 53 days after his initial symptom onset was likely a direct
esult of persistently high viral loads and lack of a humoral immune re-
ponse (evidenced by his negative IgG antibody). In addition, the viral
ulture performed off his NP specimen from day 54 post symptom onset
as positive, indicating viable virus and ongoing infectivity. ( Huang et
l., Aug ) Similarly, our second patient continued to have persistently
ow Ct values in the 20 s up to 49 days post diagnosis, indicating high
iral loads and infectious SARS-CoV-2 despite a 5 day course of Remde-
ivir and entirely asymptomatic course of infection. ( Bullard et al., 2020 )
ne study looking at 20 immunocompromised patients with hemato-
ogic malignancies also found prolonged viral shedding and viable virus
or more than 20 days in 3 patients who had received allogeneic PSCT
2 patients) or CAR T-cell therapy (1 patient) ( Aydillo et al., 2020 ). Of
ote, this study included 8 patients with lymphoma, 4, patients with
cute leukemia, 1 with chronic leukemia and 7 with multiple myeloma;
5 of which who were receiving chemotherapy, but only the allogeneic
BSCT and CAR-T cell patients had prolonged viral viability beyond 20
ays. 
During the course of his COVID-19 infection, our first patient rapidly
ost his CD33 + donor cells. Although the direct cause of his graft failure
s not clear, viral infections, such as CMV, human herpesvirus type 6, and
arvovirus have been implicated in graft failure. ( Mattsson et al., 2008 )
ARS-CoV-2 is also known to cause lymphopenia, and post-transplant
ymphopenia has also been associated with higher risk of graft failure,
eath, and viral infections. ( Dujardin et al., 2019 ) Based on the rapid
oss of his myeloid line at the time of his infection, the CMV viremia and
ARS-CoV-2 infection were thought to be likely contributors to the loss
f his graft. 
Both patients posed challenging questions in terms of treatment and
uration of SARS-CoV-2 infectivity in the PBSCT population. Our first
atient was treated with two courses of Remdesivir, including a 10 day
ourse the second time. Remdesivir did not appear to decrease the SARS-
oV-2 viral load significantly, although it did help in clearing the pa-
ient’s symptoms. ( Wang et al., 2020 ) ( Beigel et al., 2020 ) ( Goldman
t al., 2020 ) ( Spinner et al., 2020 ) In our second patient, convalescent
lasma appeared to be an effective adjunctive treatment in helping to
lear the virus quickly, noted by the significant weekly increase in Ct
alues following administration of convalescent plasma. ( Focosi et al.,
020 ) ( Liu et al., 2020 ) ( Joyner et al., 2020 ) Convalescent plasma and
onoclonal antibodies may be important treatments for those patients
ho are incapable of producing a humoral or T cell-mediated immune
A. Han, T.E. Rodriguez, E.T. Beck et al. Current Problems in Cancer: Case Reports 3 (2021) 100057 
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esponse, especially if prolonged high levels of viral shedding continue
o pose a transmission risk to others. 
Our first patient was transfusion-dependent, and his infusion center
as also attended by other immunocompromised hosts. In the contact
racing that was performed, there was an infusion nurse who was symp-
omatic with a cough and a fever 5 days after contact with the patient,
ut she tested negative by NP SARS-CoV-2 RT-PCR. Universal masking
recautions and the single patient room for this patient likely facilitated
ecreased transmission risk, but it is also possible that the exposed nurse
ad a false negative RT-PCR test given her corresponding symptoms and
nown exposure. Current CDC guidelines recommend 20 days as the du-
ation of isolation and infectivity for immunocompromised or critically
ll patients, but in allogeneic PBSCT recipients, this time frame may not
e long enough. COVID-19 may also constitute a particularly increased
hreat of graft failure in the early post HSCT period, and emphasized
recaution needs to be encouraged. This possibility of graft failure as
ell as prolonged infectivity are important arguments to prioritize vac-
ination of household members of allogeneic PBSCT recipients. Further
xploration using clinical symptoms, Ct values, and culture data to de-
ermine duration of infectivity in the HSCT recipient patient popula-
ion is warranted. ( Gniazdowski et al., 2020 ) ( Ljungman et al., 2020 )
 Waghmare et al., 2020 ) 
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